Last updated: 15 June 2019 at 1:48am EST

Kevin J Reagan Net Worth




The estimated Net Worth of Kevin J Reagan is at least $190 Tausend dollars as of 5 December 2014. Kevin Reagan owns over 3,591 units of Bio-Techne Corp stock worth over $190,413 and over the last 11 years Kevin sold TECH stock worth over $0.

Kevin Reagan TECH stock SEC Form 4 insiders trading

Kevin has made over 1 trades of the Bio-Techne Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently Kevin exercised 3,591 units of TECH stock worth $254,817 on 5 December 2014.

The largest trade Kevin's ever made was exercising 3,591 units of Bio-Techne Corp stock on 5 December 2014 worth over $254,817. On average, Kevin trades about 1,197 units every 0 days since 2013. As of 5 December 2014 Kevin still owns at least 2,591 units of Bio-Techne Corp stock.

You can see the complete history of Kevin Reagan stock trades at the bottom of the page.



What's Kevin Reagan's mailing address?

Kevin's mailing address filed with the SEC is 614 MCKINLEY PLACE N.E., , MINNEAPOLIS, MN, 55413.

Insiders trading at Bio-Techne Corp

Over the last 22 years, insiders at Bio-Techne Corp have traded over $37,160,097 worth of Bio-Techne Corp stock and bought 4,361 units worth $454,370 . The most active insiders traders include Charles R. Kummeth, Rupert Vessey und John L Higgins. On average, Bio-Techne Corp executives and independent directors trade stock every 23 days with the average trade being worth of $964,850. The most recent stock trade was executed by Kim Kelderman on 29 August 2024, trading 1,492 units of TECH stock currently worth $99,919.



What does Bio-Techne Corp do?

bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.



Complete history of Kevin Reagan stock trades at Bio-Techne Corp

Insider
Trans.
Transaktion
Gesamtpreis
Kevin J Reagan
Senior VP Biotech
Optionausübung $254,817
5 Dec 2014


Bio-Techne Corp executives and stock owners

Bio-Techne Corp executives and other stock owners filed with the SEC include: